Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study
- 13 January 2006
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 65 (8), 1118-1120
- https://doi.org/10.1136/ard.2005.046870
Abstract
This clinical trial was approved by the ethical committee of Hokkaido University …This publication has 8 references indexed in Scilit:
- HMG CoA Reductase Inhibitors Reduce Plasminogen Activator Inhibitor-1 Expression by Human Vascular Smooth Muscle and Endothelial CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase InhibitorsCirculation, 1998
- The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndromeRheumatology, 1997
- Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.Annals Of The Rheumatic Diseases, 1996
- ELEVATED von WILLEBRAND FACTOR ANTIGEN IN SYSTEMIC SCLEROSIS: RELATIONSHIP TO VISCERAL DISEASERheumatology, 1988
- Increased Factor VIII/von Willebrand Factor Antigen and von Willebrand Factor Activity in Scleroderma and in Raynaud's PhenomenonAnnals of Internal Medicine, 1981
- Preliminary criteria for the classification of systemic sclerosis (scleroderma)Arthritis & Rheumatism, 1980
- Endothelial injury in scleroderma.The Journal of Experimental Medicine, 1979